Currently Viewing:
COA 2017-ONCOLOGY PAYMENT REFORM
How Has the OCM Evolved? Year 1 Provider Updates
October 24, 2017
Will 2-Sided Risk Be a Reality in OCM?
October 24, 2017
Dr Lucio Gordan: How Practices and Payers Work Together to Implement OCM
October 24, 2017
Dr Jeff Patton Highlights Challenges Encountered With Implementing OCM
October 24, 2017
Currently Reading
Physicians Need Clearer Metrics Before Taking on 2-Sided Risk
October 25, 2017
The Commercial Payer OCM Experience: Year 1
October 25, 2017
Stakeholders Weigh-in on Payment Reform in Cancer Care
October 25, 2017
Dr Ira Klein Outlines the Biggest Challenge of Value-Based Drug Pricing
November 05, 2017
Dr Ira Klein on Pharmaceutical Interest in Alternative Payment Models
December 07, 2017
Dr Lucio Gordan: Improving Population Health Through Alternative Payment Models
December 08, 2017
Terrill Jordan: Year 1 Feedback on OCM
December 22, 2017
Sarah Cevallos: Physicians Need More Data to Determine if 2-Sided Risk is Appropriate
December 26, 2017
Terrill Jordan Discusses Making Refinements in Year 2 of OCM
January 03, 2018
Judy Berger on What Southwest Airlines Is Doing in Oncology
January 04, 2018
Bo Gamble on COA's Role in 2018
January 05, 2018
Dr Mark Fendrick on Indication-Based Drug Pricing in Cancer Care
January 07, 2018
Dr Roger Brito: What Patients Should Know About Alternative Payment Models, OCM
January 09, 2018
Sarah Cevallos on Her Advice for Practices Looking to Participate in OCM
January 10, 2018
Dr Peter Aran on Involving Providers in Development Process of New Reimbursement Models
January 11, 2018
Dr Jeff Patton Discusses Preparing for OCM, Seeing Improved Outcomes and Savings
January 12, 2018
David Merrill and John Robinson Discuss Barriers to APMs, Factors of Interest
January 15, 2018
Dr Mark Fendrick: Setting Cost-Sharing Based on Value, Not Price, in Cancer Care
January 18, 2018
Terrill Jordan Discusses the Process of Customizing an EMR to Adapt to OCM
January 19, 2018
Dr Roger Brito Discusses Implementing Alternative Payment Models and Its Challenges
January 20, 2018

Physicians Need Clearer Metrics Before Taking on 2-Sided Risk

Before physicians will be more willing to take on 2-sided risk, there needs to be clearer metrics that the physicians know will be achievable, said Sarah Cevallos, chief revenue cycle officer at Florida Cancer Specialists.


Before physicians will be more willing to take on 2-sided risk, there needs to be clearer metrics that the physicians know will be achievable, said Sarah Cevallos, chief revenue cycle officer at Florida Cancer Specialists.

Transcript (slightly edited)

What incentives will be necessary for physicians to take on 2-sided risk?

I think there will really have to be some detailed and not as much guarantees, but some really clear metrics, so that they know that they will be achievable in order for the physicians to take 2-sided risk. I think a lot of those are surrounding making sure that we’re all on the same page with accurately measuring quality and what that means to a patient. So some of those could be financial incentives or ensuring that we’re in compliance with certain measure that the physician feels that is really going to drive quality for the oncology patients. You know, making sure that the totality of the patient Is really well defined versus just what’s happening in the clinic at the oncology office.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up